Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.10
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $238.5M | $1.60B | $3.71B | $6.39B | $15.49B | $2.53B | $134.0M | $1.34B |
| Cost of revenue | $139.5M | $579.0M | $2.37B | $5.00B | $15.25B | $2.24B | $1.37B | $1.39B |
| Gross profit | $98.9M | $1.02B | $1.34B | $1.39B | $2.16B | −$2.15B | −$1.22B | −$51.2M |
| Gross margin | 41.5% | 63.7% | 36.2% | 21.7% | 13.9% | -85.0% | -907.3% | -3.8% |
| R&D | $0 | $0 | $0 | $334.6M | $1.91B | $4.83B | $1.51B | $47.6M |
| Operating income | $79.8M | $759.8M | $640.3M | −$2.16B | −$4.61B | −$53.18B | −$12.14B | −$8.96B |
| EBITDA | $93.8M | $683.0M | $662.4M | −$1.15B | −$3.47B | −$24.40B | −$13.36B | −$7.90B |
| Net income | $46.3M | $301.4M | −$1.69B | −$5.02B | −$7.39B | −$56.27B | −$27.66B | −$11.93B |
| Net margin | 19.4% | 18.9% | -45.6% | -78.5% | -47.7% | -2223.2% | -20640.4% | -890.5% |
| EPS (diluted) | 0.01 | 0.04 | -0.20 | -0.58 | -0.85 | -5.85 | -1.37 | -1.10 |
Annual figures · source: Financial Modeling Prep
CHINA EVERGRANDE NEW EGY
No one on the platform currently holds EVGRF.
No tracked institution reports a position in EVGRF as of their last filing.
No one on the platform has traded EVGRF yet.
| +0.47% |
| $224M |
| — |
| MKLNFM1 Kliniken AG | $11.73 | +0.00% | $215M | — |
| OPORFhVIVO plc | $0.11 | +0.00% | $75M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.0× sales vs its 2.3× historical median P/S.
Fair value ≈ $3.83 · price $0.00 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.